Reversal of hepatic fibrosis -- fact or fantasy? - PubMed (original) (raw)
Review
. 2006 Feb;43(2 Suppl 1):S82-8.
doi: 10.1002/hep.20974.
Affiliations
- PMID: 16447275
- DOI: 10.1002/hep.20974
Review
Reversal of hepatic fibrosis -- fact or fantasy?
Scott L Friedman et al. Hepatology. 2006 Feb.
Abstract
The prospect of reversing hepatic fibrosis has generated great interest now that basic science advances are being translated into promising new antifibrotic therapies. It is appropriate to recognize both the historical advances that created the framework for these successes, and the important role that Hepatology has played in disseminating them. A sense of urgency underlies this effort as the epidemics of HCV and NASH are becoming associated with advancing fibrosis. To maintain progress and minimize confusion among investigators and clinicians it is essential to standardize terms referring to fibrosis 'reversal' and 'regression.' There must also be rapid optimization of non-invasive markers of fibrosis to relieve this current bottleneck to conducting clinical trials. Progress in identifying genetic determinants of fibrosis could further refine patient selection for clinical trials and shorten their duration, as well as unearthing new directions of scientific inquiry. Realistic expectations for successful anti-fibrotic therapies reflect solid evidence of fibrosis regression in patients treated effectively for viral liver disease, as well as growing clarity in the understanding mechanisms of extracellular matrix production and degradation. The paradigms of stellate cell activation and apoptosis remain valuable frameworks for understanding pathways of hepatic fibrogenesis and fibrosis regression, respectively. Continued progress is essential in order to identify the determinants and dynamics of fibrosis reversibility, to discover additional targets for anti-fibrotic therapy, and to develop customized multi-drug regimens. These advances are sure to be captured in the next 25 years by Hepatology , and to profoundly impact the prognosis of patients with chronic liver disease.
Similar articles
- Liver fibrosis: from the bench to clinical targets.
Pinzani M, Rombouts K. Pinzani M, et al. Dig Liver Dis. 2004 Apr;36(4):231-42. doi: 10.1016/j.dld.2004.01.003. Dig Liver Dis. 2004. PMID: 15115333 Review. - [Liver fibrosis: pathophysiology, diagnosis and treatment].
Pár A, Pár G. Pár A, et al. Orv Hetil. 2005 Jan 2;146(1):3-13. Orv Hetil. 2005. PMID: 15715367 Review. Hungarian. - Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
Friedman SL. Friedman SL. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):98-105. doi: 10.1038/ncpgasthep0055. Nat Clin Pract Gastroenterol Hepatol. 2004. PMID: 16265071 Review. - Hepatic fibrosis--role of hepatic stellate cell activation.
Safadi R, Friedman SL. Safadi R, et al. MedGenMed. 2002 Jul 15;4(3):27. MedGenMed. 2002. PMID: 12466770 Review. - Hepatic stellate cells and the reversal of fibrosis.
Kisseleva T, Brenner DA. Kisseleva T, et al. J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S84-7. doi: 10.1111/j.1440-1746.2006.04584.x. J Gastroenterol Hepatol. 2006. PMID: 16958681 Review.
Cited by
- Fibro-Stenosing Crohn's Disease: What Is New and What Is Next?
Solitano V, Dal Buono A, Gabbiadini R, Wozny M, Repici A, Spinelli A, Vetrano S, Armuzzi A. Solitano V, et al. J Clin Med. 2023 Apr 22;12(9):3052. doi: 10.3390/jcm12093052. J Clin Med. 2023. PMID: 37176493 Free PMC article. Review. - Preparation of Betulinic Acid Galactosylated Chitosan Nanoparticles and Their Effect on Liver Fibrosis.
Wu ZC, Liu XY, Liu JY, Piao JS, Piao MG. Wu ZC, et al. Int J Nanomedicine. 2022 Sep 14;17:4195-4210. doi: 10.2147/IJN.S373430. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36134203 Free PMC article. - Shugan Huoxue Huayu Fang attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting transforming growth factor-β1/Smad signaling.
Liu L, Guo HB, Shao CP, Wang L, Xu YQ, Zhou YM. Liu L, et al. J Tradit Chin Med. 2022 Feb;42(1):65-72. doi: 10.19852/j.cnki.jtcm.20210624.001. J Tradit Chin Med. 2022. PMID: 35294124 Free PMC article. - Fibrosis and hepatic regeneration mechanism.
Zuñiga-Aguilar E, Ramírez-Fernández O. Zuñiga-Aguilar E, et al. Transl Gastroenterol Hepatol. 2022 Jan 25;7:9. doi: 10.21037/tgh.2020.02.21. eCollection 2022. Transl Gastroenterol Hepatol. 2022. PMID: 35243118 Free PMC article. Review. - A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn's Disease.
Li Z, Lu B, Lin J, He S, Huang L, Wang Y, Meng J, Li Z, Feng ST, Lin S, Mao R, Li XH. Li Z, et al. Front Mol Biosci. 2021 Nov 11;8:762355. doi: 10.3389/fmolb.2021.762355. eCollection 2021. Front Mol Biosci. 2021. PMID: 34859052 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical